乳房切除术后光子与调强质子放疗的急性皮肤反应对比分析
本研究比较了176例单侧非炎性乳腺癌患者乳房切除术后接受调强质子治疗(IMPT)或光子放疗(XRT)的靶区覆盖、皮肤剂量、医生评估的不良事件及患者报告的皮肤结局。结论认为两种模式的皮肤不良事件均较轻且总体可比,强调IMPT计划中皮肤约束的重要性。
要点
- IMPT计划中皮肤剂量约束对优化皮肤剂量至关重要。
核心结论
- 患者和医生报告的皮肤不良事件在IMPT与XRT之间均较轻且可比。
- 这些发现强调了IMPT计划中皮肤约束对滴定最佳皮肤剂量的重要性。
研究设计与样本
- 纳入176例单侧非炎性乳腺癌女性患者,接受乳房切除术后放疗至50 Gy(RBE),其中IMPT组93例、XRT组83例。
- 两种模式的皮肤计划目标均优先要求≥90%的皮肤体积接受>90%的处方剂量,同时保持剂量均匀性。
- IMPT计划目标限制1 cc皮肤剂量≤105%处方剂量,理想约束为≤96%。
- 比较靶区和皮肤剂量学、急性CTCAE≥2级皮炎及PRO-CTCAE皮肤特异性患者报告结局。
主要发现
- XRT计划的皮肤D0.01cc、D1cc和D10cc中位数均高于IMPT计划,但差异均小于3%。
关键数值与推荐
- 皮肤计划目标:≥90%皮肤体积接受>90%处方剂量。
- IMPT计划约束:1 cc皮肤剂量≤105%处方剂量,理想≤96%。
- 急性皮炎按CTCAE分级,患者报告结局采用PRO-CTCAE评估。
临床怎么用
- IMPT和XRT均可用于乳房切除术后放疗,急性皮肤反应总体较轻且可比。
- IMPT计划中应重视皮肤剂量约束,以优化皮肤剂量并可能减少长期皮肤颜色改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to compare target coverage, skin dose, physician-assessed adverse events, and patient-reported skin outcomes in a large cohort of patients receiving postmastectomy intensity modulated proton therapy (IMPT) or photon radiation therapy (XRT). METHODS AND MATERIALS: Women with unilateral, noninflammatory breast cancer treated with postmastectomy radiation therapy using IMPT or XRT to 50 Gy relative biological effectiveness (RBE) were included. Skin planning objectives for both modalities prioritized ≥90% of the skin volume receiving >90% of the prescription dose, which is expected to control microscopic disease, while maintaining dose homogeneity. IMPT planning objectives limited the dose to 1 cc of skin to ≤105% of the prescription dose, with an ideal constraint of ≤96%. Target and skin dosimetry were evaluated. Acute Common Toxicity Criteria for Adverse Events (CTCAE) grade ≥2 dermatitis and skin-specific patient-reported outcomes using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) were compared between modalities. RESULTS: Among 176 women (93 IMPT, 83 XRT), the median skin D0.01cc, D1cc, and D10cc were higher in XRT plans than in IMPT plans, although the differences were all less than 3%. Acute grade ≥2 dermatitis occurred in 47% (IMPT) and 48% (XRT) and was not associated with treatment modality (P = .91). Grade 3 dermatitis occurred in 3% (IMPT) and 7% (XRT) (P = .22), with no grade 4 events. At 12 months post-RT, XRT patients reported more skin color changes than IMPT patients (26% vs 6%, P = .04), the only significantly different patient-reported skin outcome. CONCLUSIONS: Patient and provider-reported adverse skin events were mild and comparable between IMPT and XRT. These findings highlight the importance of skin constraints for IMPT planning to titrate an optimal skin dose.
引用
- Gergelis KR, Afzal A, Mullikin TC, et al. Comparative Analysis of Acute Skin Reactions After Postmastectomy Photon and Intensity Modulated Proton Therapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 42269789. doi:10.1016/j.ijrobp.2026.05.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。